hydrocodone bitartrate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   75 News 
  • ||||||||||  hydrocodone bitartrate / Generic mfg., naltrexone / Generic mfg.
    SMART (Exhibit Hall) -  Jul 31, 2024 - Abstract #PAINWeek2024PAINWeek_229;    
    In all treatment periods O2P Hydrocodone was generally well tolerated in all subjects with no serious adverse events reported. Study drug related Treatment-Emergent Adverse Events (TEAEs) occurrence was 19.
  • ||||||||||  Xtampza ER (oxycodone) / Collegium Pharma
    Curbing Opioid Abuse: Real-World Evidence of Abuse-Deterrent Formulations (Exhibit Hall) -  Jul 31, 2024 - Abstract #PAINWeek2024PAINWeek_161;    
    Study drug related Treatment-Emergent Adverse Events (TEAEs) occurrence was 19. 3-4 To date, there are 4 opioids (1 immediate release [IR] and 3 extended release [ER]) with US Food and Drug Administration (FDA)
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue
    Journal:  Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective. (Pubmed Central) -  Nov 17, 2021   
    However, cost, loopholes in deterrence mechanism, and possible diversion to other substances hinder their role in the opioid crisis. Multiple approaches must be employed to improve opioid safety, and further post-marketing and real-world analyses should be performed on available opioid formulations to assess their impact on abuse-related adverse events.
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue, Xtampza ER (oxycodone) / Collegium Pharma
    Non-Medical Use and Diversion of XTAMPZA ER in the General Population () -  Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_52;    
    XTAMPZA ER was rarely non-medically used independently of these two comparators. While NMU of XTAMPZA ER was less prevalent than comparators, the motivations and behaviors among those who non-medically used were similar.
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue
    Abuse and misuse of XTAMPZA® ER relative to other opioid analgesics () -  Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_7;    
    No abuse or misuse of XTAMPZA ER via unintended routes of administration was reported in the Poison Center Program. The proportion of cases involving use via unintended routes of administration was lower for XTAMPZA ER than for comparator drug groups among individuals entering treatment for opioid use disorders.
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue, Arymo (morphine) / Zyla Life Sciences
    Journal, HEOR:  Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization. (Pubmed Central) -  Mar 14, 2020   
    An ADF opioid-including reformulated oxycodone hydrochloride (HCl) controlled-release (CR; reformulated OxyContin), morphine sulfate and naltrexone HCl extended-release (ER; Embeda), and hydrocodone bitartrate ER (Hysingla ER)-was considered covered if it was listed on the health plan's formulary...Broad formulary coverage of ADF opioids is associated with reduced rates of opioid abuse or overdose in real-world managed care populations. Health plan administrators and policymakers may consider improving the formulary coverage of ADF opioids as a strategy to ensure appropriate patient access to necessary pain medications while mitigating risk for opioid abuse or overdose.
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue
    Preclinical, Journal:  An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing. (Pubmed Central) -  Aug 21, 2019   
    ...In the present study, a chewing apparatus was utilized to develop an in vitro chewing method for Hysingla ER tablets, a prescription opioid with labeling describing abuse deterrence via the oral route when chewed...By contrast, an opioid product with labeling that does not describe abuse-deterrent properties showed lower resistance to chewing resulting in higher drug release. The results of the present study suggest that the chewing methodology evaluated in this work may provide a useful in vitro tool for the comparative evaluation of AD properties.
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue, Zohydro ER (hydrocodone bitartrate extended release) / Pernix
    Clinical, Journal:  Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain. (Pubmed Central) -  May 30, 2019   
    HYD demonstrated a safety profile typical of µ opioids; nausea, constipation, vomiting, and dizziness were the most frequently reported opioid-related adverse events during the study.  In patients with chronic pain who received HYD over a 52-week period, treatment was generally well tolerated and provided effective analgesia among those who rotated from a pain regimen primarily consisting of IR oxycodone.